SCHEMBL24923802

SCHEMBL24923802

CC(C)Oc1ccc(C2CCC(=O)C2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.57
POLB P06746 1/20 0.51
GAA P10253 1/20 0.44
CYP2C19 P33261 1/20 0.44
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
ALDH1A3 P47895 1/20 0.43
ESR2 Q92731 2/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.42
GLA P06280 1/20 0.40
PKM P14618 1/20 0.39
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
PARP10 Q53GL7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4601394 0.90 TSHR (0.56) TSHRPOLBGAACYP2C19PDE4A
SCHEMBL2149701 0.84 CYP1A2 (0.48) TSHRPOLBGAACYP2C19PDE4A
SCHEMBL30368498 0.83 TSHR (0.60) TSHRPOLBGAACYP2C19ALDH1A3
SCHEMBL2044509 0.81 ALDH1A1 (0.54) PDE4APDE4BPDE4CPDE4DESR2
SCHEMBL2044506 0.81 ALDH1A1 (0.54) PDE4APDE4BPDE4CPDE4DESR2
SCHEMBL27471526 0.81 ALDH1A1 (0.54) PDE4APDE4BPDE4CPDE4DESR2
SCHEMBL10699907 0.78 ESR2 (0.46) GAAPDE4APDE4BPDE4CPDE4D
SCHEMBL7002551 0.77 HRH3 (0.47) PDE4APDE4BPDE4CPDE4DESR2
SCHEMBL14446350 0.75 TSHR (0.54) TSHRPOLBGAACYP2C19ALDH1A3
SCHEMBL7004274 0.75 ESR2 (0.50) POLBGAAPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2024-07-09 US disclosed
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2024-07-09 US disclosed
US-20240150324-A1 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV ASSEMBLY BIOSCIENCES, INC. 2024-05-09 US disclosed
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2023-01-24 US disclosed
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2023-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV HCCS, HAVCR2, MAVS TSHR 3539/4885POLB 363/4885GAA 2553/4885
US-20240150324-A1 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV HCCS, HAVCR2, MAVS TSHR 3539/4885POLB 363/4885GAA 2553/4885
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV HCCS, HAVCR2, MAVS TSHR 3539/4885POLB 363/4885GAA 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.